[Atypical femoral fractures in long-term osteoporotic treatment with bisphosphonates].
Recently, atypical femoral fractures, especially at the proximal part, were reported in the literature. Most of the reports discussed the relationship between those atypical fractures and chronic use of bisphosphonate drugs as prophylactic treatment for osteoporosis. As a result, the FDA (US Food and Drug Administration) published a statement on October 2010, which was the conclusion of a multidisciplinary working group. The FDA decided to add warnings for every bisphosphonate drug which was given as prophylactic treatment for osteoporosis in the USA. In this review, we will present the bisphosphonate drugs, the presenting symptoms of patients who suffer from the pathologic fracture, the radiologic characteristics and the surgical treatment. We will present the work of a Task Force of the American Society for Bone and Mineral Research and the FDA statements.
Department of Orthopedics, Chaim Sheba Medical Center, Tel-HaShomer, Israel. ranthein@gmail.com
Ran
R
Thein
Shay
S
Tenenbaum
Ofir
O
Chechick
Oded
O
Hershkovitz
Aharon
A
Chechik
Israel
I
Caspi
D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004348:Drug Labeling; D005264:Femoral Fractures / Q000453:epidemiology / Q000209:etiology* / Q000473:pathology; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy; D013997:Time Factors; D014481:United States; D014486:United States Food and Drug Administration
D050071:Bone Density Conservation Agents; D004164:Diphosphonates